文献速递泌尿系感染

脂质体制剂A型肉毒毒素膀胱灌注治疗间质性膀胱炎/膀胱疼痛综合征的前瞻性、多中心、双盲、随机试验

A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome.
PubMed 文献 · J Urol · 2017-02-12

主要终点为基线至治疗后4周O'Leary-Sant症状评分的平均变化。结果三组均有改善,但组间无差异,未发现显著不良事件;作者认为脂质体A型肉毒毒素未能显示阳性概念验证,疗效可能源于显著的安慰剂效应。

要点

  • 脂质体A型肉毒毒素膀胱灌注在O'Leary-Sant症状评分、ICSI、ICPI、疼痛视觉模拟评分和总体反应评估上较基线改善。
  • 三组间改善程度无差异,脂质体A型肉毒毒素未优于A型肉毒毒素或安慰剂。
  • 所有组均未发现显著不良事件,作者认为疗效可能源于显著的安慰剂效应。

核心结论

  • 脂质体A型肉毒毒素与A型肉毒毒素或安慰剂相比未能显示阳性概念验证。
  • 单次脂质体A型肉毒毒素膀胱灌注与中重度间质性膀胱炎/膀胱疼痛综合征患者基线相比症状减轻,但该效应可能源于显著的安慰剂效应。

研究设计与样本

  • 2中心、双盲、随机、安慰剂对照、研究者发起的试验。
  • 主要终点为基线至治疗后4周O'Leary-Sant症状评分(含ICSI和ICPI)的平均变化。

主要发现

  • 治疗后4周内三组疼痛评分和O'Leary-Sant症状评分均改善。
  • 脂质体A型肉毒毒素组O'Leary-Sant症状评分平均下降7.38±8.75,ICSI下降4.00±4.28,ICPI下降3.35±5.11,疼痛视觉模拟评分下降1.64±2.52,总体反应评估升高1.35±1.28。
  • 三组间改善程度无差异。
  • 所有组均未发现显著不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravesical instillation of liposomal formulated botulinum toxin A (lipotoxin) has shown therapeutic effects as treatment of refractory overactive bladder without needle injections. We assessed lipotoxin to treat refractory interstitial cystitis/bladder pain syndrome. MATERIALS AND METHODS: This 2-center, double-blind, randomized, placebo controlled, physician initiated study enrolled patients with refractory interstitial cystitis/bladder pain syndrome. A total of 31 patients were assigned to intravesical instillation of lipotoxin (onabotulinumtoxinA 200 U with 80 mg sphingomyelin), 28 were assigned to onabotulinumtoxinA 200 U in normal saline and 31 were assigned to normal saline alone. The primary end point was the average change in O'Leary-Sant symptom scores, including ICSI (Interstitial Cystitis Symptom Index) and ICPI (Interstitial Cystitis Problem Index) between baseline and 4 weeks after treatment. Other end points included the average changes in a 3-day voiding diary, a visual analog scale for pain and a global response assessment of patient satisfaction. RESULTS: Improvements in the pain scale and O'Leary-Sant symptom scores occurred in all 3 groups by 4 weeks after treatment. Lipotoxin instillation was associated with a statistically significant decrease in O'Leary-Sant symptom scores (mean ± SD 7.38 ± 8.75), ICSI (4.00 ± 4.28), ICPI (3.35 ± 5.11) and the visual analog scale pain scale (1.64 ± 2.52), and an increase in the global response assessment (1.35 ± 1.28). However, there was no difference in improvement among the 3 groups. No significant adverse events were found in any group. CONCLUSIONS: Lipotoxin failed to demonstrate a positive proof of concept compared to onabotulinumtoxinA or placebo. However, a single intravesical instillation of lipotoxin was associated with decreased interstitial cystitis/bladder pain syndrome symptoms compared to baseline in patients with moderate to severe interstitial cystitis/bladder pain syndrome. The effect was likely due to a significant placebo effect.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chuang YC, Kuo HC. A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2017. PMID: 28202358. doi:10.1016/j.juro.2017.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。